AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38943163 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery risk level
Number of subjects: 2003
Study 38943163 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical and laboratory tests
Number of subjects: 2003
Study 38943169 — intervention group
Group type: EXPERIMENTAL
Intervention: BeSmooth BMS (Bentley Innomed GmbH)
Number of subjects: 98
Study 38943169 — intervention group
Group type: COMPARATOR
Intervention: BeGraft CS (Bentley Innomed GmbH)
Number of subjects: 98
Study 38943176 — intervention group
Group type: EXPERIMENTAL
Intervention: HOW R U? intervention delivered by intergenerational volunteers
Number of subjects: 0
Study 38943176 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard same-generation peer support HOW R U? intervention
Number of subjects: 0
Study 38943176 — intervention group
Group type: COMPARATOR
Intervention: Common wait-list control group
Number of subjects: 0
Study 38943178 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent supervised tele-rehabilitation
Number of subjects: 0
Study 38943178 — intervention group
Group type: COMPARATOR
Intervention: Home-based self-rehabilitation
Number of subjects: 0
Study 38943179 — intervention group
Group type: COMPARATOR
Intervention: Routine supplementation (400 IU/day with established feedings)
Number of subjects: 180
Study 38943179 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased supplementation (800 IU/day with any feedings)
Number of subjects: 180
Study 38943192 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilobelimab (C5a inhibitor)
Number of subjects: 368
Study 38943197 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 sessions of process-based working memory training (experimental group)
Number of subjects: 94
Study 38943197 — intervention group
Group type: COMPARATOR
Intervention: Active control group (multi-domain training)
Number of subjects: 94
Study 38943197 — intervention group
Group type: COMPARATOR
Intervention: Passive control group
Number of subjects: 94
Study 38943203 — intervention group
Group type: EXPERIMENTAL
Intervention: miLab™ (automated mode)
Number of subjects: 190
Study 38943203 — intervention group
Group type: EXPERIMENTAL
Intervention: miLab™ (corrected mode)
Number of subjects: 190
Study 38943203 — intervention group
Group type: EXPERIMENTAL
Intervention: miLab™
Number of subjects: 190
Study 38943204 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically matched incremental hemodialysis (CMIHD)
Number of subjects: 0
Study 38943204 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemodialysis (CHD)
Number of subjects: 0
Study 38943294 — intervention group
Group type: EXPERIMENTAL
Intervention: Short messages informing relatives during surgery (preparations for surgery have begun, surgery has started, surgery is ongoing, surgery is completed)
Number of subjects: 84
Study 38943294 — intervention group
Group type: COMPARATOR
Intervention: Control group (no short messages)
Number of subjects: 84
Study 38943294 — intervention group
Group type: EXPERIMENTAL
Intervention: Short messages informing relatives during surgery
Number of subjects: 84
Study 38943664 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapanisertib (5 mg daily)
Number of subjects: 46
Study 38943710 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate-to-albumin ratio (LAR)
Number of subjects: 219
Study 38943710 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin levels
Number of subjects: 219
Study 38943710 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol levels
Number of subjects: 219
Study 38943710 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL cholesterol levels
Number of subjects: 219
Study 38943710 — intervention group
Group type: EXPERIMENTAL
Intervention: LAR, albumin, total cholesterol, and HDL-cholesterol levels
Number of subjects: 219
Study 38943838 — intervention group
Group type: EXPERIMENTAL
Intervention: Music during ROP examination
Number of subjects: 28
Study 38943838 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 28
Study 38943928 — intervention group
Group type: EXPERIMENTAL
Intervention: Luvadaxistat 50 mg
Number of subjects: 256
Study 38943928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 38943928 — intervention group
Group type: EXPERIMENTAL
Intervention: Luvadaxistat 125 mg
Number of subjects: 256
Study 38943928 — intervention group
Group type: EXPERIMENTAL
Intervention: Luvadaxistat 500 mg
Number of subjects: 256
Study 38944045 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural cycle endometrial preparation
Number of subjects: 1428
Study 38944045 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified natural cycle endometrial preparation
Number of subjects: 1428
Study 38944045 — intervention group
Group type: COMPARATOR
Intervention: Artificial cycle endometrial preparation
Number of subjects: 1428
Study 38944147 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma YKL-40 levels in drinkers (highest quartile)
Number of subjects: 3267
Study 38944147 — intervention group
Group type: COMPARATOR
Intervention: Plasma YKL-40 levels in nondrinkers (lowest quartile)
Number of subjects: 3267
Study 38944147 — intervention group
Group type: EXPERIMENTAL
Intervention: Log-transformed YKL-40 increase for light drinkers
Number of subjects: 3267
Study 38944147 — intervention group
Group type: EXPERIMENTAL
Intervention: Log-transformed YKL-40 increase for heavy drinkers
Number of subjects: 3267
Study 38944418 — intervention group
Group type: EXPERIMENTAL
Intervention: AF burden >0.2%
Number of subjects: 417
Study 38944418 — intervention group
Group type: EXPERIMENTAL
Intervention: AF episode duration >1 hour
Number of subjects: 417
Study 38944418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate AF burden (0.2-1.9%)
Number of subjects: 417
Study 38944418 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of AF episodes >147
Number of subjects: 417
Study 38944418 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher AF burden and longer episode duration
Number of subjects: 417
Study 38944418 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher number of episodes
Number of subjects: 417
Study 38944806 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) and androgen deprivation therapy (ADT) for at least 24 months
Number of subjects: 81
Study 38945140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment targeting systolic blood pressure of less than 120 mm Hg
Number of subjects: 11255
Study 38945140 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment targeting systolic blood pressure of less than 140 mm Hg
Number of subjects: 11255
Study 38945140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 11255
Study 38945140 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 11255
Study 38945791 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab, doxorubicin, vinblastine, and dacarbazine (N-AVD)
Number of subjects: 0
Study 38945791 — intervention group
Group type: COMPARATOR
Intervention: Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (BV-AVD)
Number of subjects: 0
Study 38945800 — intervention group
Group type: EXPERIMENTAL
Intervention: Furmonertinib combined with carboplatin and pemetrexed for 4 cycles, then furmonertinib and pemetrexed as maintenance therapy (Arm B2)
Number of subjects: 0
Study 38945800 — intervention group
Group type: EXPERIMENTAL
Intervention: Furmonertinib combined with carboplatin and pemetrexed for 4 cycles, then furmonertinib and pemetrexed as maintenance therapy plus bevacizumab (Arm B3)
Number of subjects: 0
Study 38945800 — intervention group
Group type: COMPARATOR
Intervention: Furmonertinib monotherapy (Arm B1)
Number of subjects: 0
Study 38946010 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure (BP) control
Number of subjects: 8016
Study 38946010 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving a BP target of < 120/80 mmHg
Number of subjects: 8016
Study 38946384 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-fluid challenge (MFC) with 100 mL of crystalloids
Number of subjects: 33
Study 38946384 — intervention group
Group type: COMPARATOR
Intervention: Short-time low positive end-expiratory pressure (PEEP) challenge (SLPC) with an additional 5 cmH2O PEEP
Number of subjects: 33
Study 38946484 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBV-184 (0.07 ug/kg initially, with 2- to 3-fold dose increases)
Number of subjects: 15
Study 38946973 — intervention group
Group type: EXPERIMENTAL
Intervention: JAK inhibitor tofacitinib
Number of subjects: 10
Study 38947035 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 633
Study 38947035 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 633
Study 38947064 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 hours of therapeutic cooling
Number of subjects: 1800
Study 38947064 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 hours of therapeutic cooling
Number of subjects: 1800
Study 38947064 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 hours of therapeutic cooling
Number of subjects: 1800
Study 38947064 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter and longer duration arms (to be opened during the trial)
Number of subjects: 1800
Study 38947064 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic hypothermia
Number of subjects: 1800
Study 38947088 — intervention group
Group type: EXPERIMENTAL
Intervention: MRSA nasal swab PCR testing in addition to usual care
Number of subjects: 0
Study 38947088 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study 38947093 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest-X-ray (CXR) with computer-aided detection (CAD) algorithms
Number of subjects: 1392
Study 38947093 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert TB Host Response (HR) testing
Number of subjects: 1392
Study 38947093 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) testing
Number of subjects: 1392
Study 38947093 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert HR-CAD4TB (sequential negative screening)
Number of subjects: 1392
Study 38947093 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP-CAD4TB (sequential negative screening)
Number of subjects: 1392
Study 38947093 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert HR-CAD4TB (sequential positive screening)
Number of subjects: 1392
Study 38947097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold milk feeding
Number of subjects: 26
Study 38947097 — intervention group
Group type: COMPARATOR
Intervention: Room temperature milk feeding
Number of subjects: 26
Study 38947220 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing (CPET)
Number of subjects: 611
Study 38947220 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen uptake at peak exercise (VO2)
Number of subjects: 611
Study 38947228 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX-351 (liposomal daunorubicin and cytarabine) administered at 135 units/m
Number of subjects: 38
Study 38947228 — intervention group
Group type: COMPARATOR
Intervention: Standard anthracyclines (in ongoing randomized trial)
Number of subjects: 38
Study 38947304 — intervention group
Group type: EXPERIMENTAL
Intervention: BLS simulation training using AHA-BLS-2020 guidelines
Number of subjects: 102
Study 38947304 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 102
Study 38947323 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary cytoreductive surgery
Number of subjects: 22
Study 38947323 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 22
Study 38947323 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy scoring
Number of subjects: 22
Study 38947323 — intervention group
Group type: COMPARATOR
Intervention: Cytoreductive surgery
Number of subjects: 22
Study 38947738 — intervention group
Group type: EXPERIMENTAL
Intervention: Search engine ads
Number of subjects: 0
Study 38947738 — intervention group
Group type: EXPERIMENTAL
Intervention: Paid advertising within a national testing company
Number of subjects: 0
Study 38947738 — intervention group
Group type: EXPERIMENTAL
Intervention: Paid advertising within a regional testing company
Number of subjects: 0
Study 38947738 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic health record messages
Number of subjects: 0
Study 38947738 — intervention group
Group type: EXPERIMENTAL
Intervention: Word of mouth
Number of subjects: 0
Study 38948108 — intervention group
Group type: EXPERIMENTAL
Intervention: High prenatal DHA supplementation
Number of subjects: 0
Study 38948108 — intervention group
Group type: COMPARATOR
Intervention: Low prenatal DHA supplementation
Number of subjects: 0
Study 38948164 — intervention group
Group type: EXPERIMENTAL
Intervention: Visepegenatide
Number of subjects: 273
Study 38948164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 273
Study 38948455 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk Density (BD) synthetic CT
Number of subjects: 36
Study 38948455 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Stratification (TS) synthetic CT
Number of subjects: 36
Study 38948455 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-Learning (DL) synthetic CT
Number of subjects: 36
Study 38948487 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment plus exercise therapy
Number of subjects: 80
Study 38948487 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture plus exercise therapy
Number of subjects: 80
Study 38948837 — intervention group
Group type: EXPERIMENTAL
Intervention: MUC1 tumor antigen vaccine
Number of subjects: 68
Study 38949541 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 2292
Study 38949541 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 2292
Study 38949541 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 2292
Study 38949541 — intervention group
Group type: COMPARATOR
Intervention: Labetalol vs Standard Care
Number of subjects: 2292
Study 38949541 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine vs Standard Care
Number of subjects: 2292
Study 38949541 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol vs Nifedipine
Number of subjects: 2292
Study 38949541 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol and Nifedipine
Number of subjects: 2292
Study 38949715 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete decongestive therapy (CDT) 5 days a week for 3 weeks in MetS group
Number of subjects: 40
Study 38949715 — intervention group
Group type: COMPARATOR
Intervention: Complete decongestive therapy (CDT) 5 days a week for 3 weeks in control group
Number of subjects: 40
Study 38949758 — intervention group
Group type: EXPERIMENTAL
Intervention: Vupanorsen 80 mg
Number of subjects: 18
Study 38949758 — intervention group
Group type: EXPERIMENTAL
Intervention: Vupanorsen 160 mg
Number of subjects: 18
Study 38949758 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 18
Study 38949814 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Milking (UCM)
Number of subjects: 971
Study 38949814 — intervention group
Group type: COMPARATOR
Intervention: Early Cord Clamping (ECC)
Number of subjects: 971
Study 38949813 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nudges (clinician peer comparisons + patient priming questionnaires)
Number of subjects: 4450
Study 38949813 — intervention group
Group type: COMPARATOR
Intervention: Clinician nudge only (active control + weekly peer comparisons)
Number of subjects: 4450
Study 38949813 — intervention group
Group type: COMPARATOR
Intervention: Patient nudge only (active control + preclinic electronic communication)
Number of subjects: 4450
Study 38949813 — intervention group
Group type: COMPARATOR
Intervention: Active control (clinician text message reminders)
Number of subjects: 4450
Study 38949862 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention with high immersion levels
Number of subjects: 252
Study 38949862 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 252
Study 38949906 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 hr of SOP training (n = 70)
Number of subjects: 216
Study 38949906 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 hr of SOP training (n = 73)
Number of subjects: 216
Study 38949906 — intervention group
Group type: COMPARATOR
Intervention: 10 hr of internet navigation control training (n = 73)
Number of subjects: 216
Study 38950286 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizanlizumab
Number of subjects: 11
Study 38950311 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-proANP and NT-proBNP combined with clinical variables
Number of subjects: 621
Study 38950311 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-proANP and NT-proBNP
Number of subjects: 621
Study 38950321 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (SCRT) followed by six cycles of consolidation immunochemotherapy with capecitabine and oxaliplatin and toripalimab (Group A)
Number of subjects: 121
Study 38950321 — intervention group
Group type: COMPARATOR
Intervention: Two cycles of induction immunochemotherapy followed by SCRT and the rest four doses (Group B)
Number of subjects: 121
Study 38950376 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment based on voiding diaries (dDAVP for nocturnal polyuria with normal MVV; enuresis alarm for reduced MVV and no nocturnal polyuria)
Number of subjects: 324
Study 38950376 — intervention group
Group type: COMPARATOR
Intervention: Randomly allocated treatment (dDAVP or alarm)
Number of subjects: 324
Study 38950397 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 196
Study 38950397 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture (SA)
Number of subjects: 196
Study 38950423 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet adherence
Number of subjects: 178
Study 38950423 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillota/Bacteroidota ratio
Number of subjects: 178
Study 38950423 — intervention group
Group type: EXPERIMENTAL
Intervention: Food consumption patterns
Number of subjects: 178
Study 38950423 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiota alterations
Number of subjects: 178
Study 38950555 — intervention group
Group type: EXPERIMENTAL
Intervention: DLL3-targeted imaging tracer
Number of subjects: 18
Study 38950555 — intervention group
Group type: EXPERIMENTAL
Intervention: DLL3 PET-CT imaging
Number of subjects: 18
Study 38950668 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic physician notification with customized guideline recommendations for the management of severe aortic stenosis
Number of subjects: 940
Study 38950668 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no notification)
Number of subjects: 940
Study 38950668 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic physician notification
Number of subjects: 940
Study 38950689 — intervention group
Group type: EXPERIMENTAL
Intervention: V-Wave interatrial shunt device implantation at the time of MitraClip procedure
Number of subjects: 0
Study 38950689 — intervention group
Group type: COMPARATOR
Intervention: MitraClip procedure
Number of subjects: 0
Study 38950925 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib first-line maintenance therapy
Number of subjects: 487
Study 38950931 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (21 mL of 2% lidocaine and 50 μg fentanyl)
Number of subjects: 22
Study 38950987 — intervention group
Group type: EXPERIMENTAL
Intervention: AI decision support software
Number of subjects: 228
Study 38950987 — intervention group
Group type: COMPARATOR
Intervention: No AI decision support software (control group)
Number of subjects: 228
Study 38950991 — intervention group
Group type: EXPERIMENTAL
Intervention: Full/near-full optical treatment requiring wear for at least half their waking hours for 24 weeks.
Number of subjects: 0
Study 38950991 — intervention group
Group type: EXPERIMENTAL
Intervention: Full/near-full optical treatment
Number of subjects: 0
Study 38950995 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin type A (BoNT-A) treatment at different timings
Number of subjects: 960
Study 38950995 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation without BoNT-A treatment
Number of subjects: 960
Study 38950994 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerina (CBT-based mobile app) for 6 weeks
Number of subjects: 90
Study 38950994 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (optional on-campus well-being services for 6 weeks)
Number of subjects: 90
Study 38950993 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Exposure Therapy (GET)
Number of subjects: 220
Study 38950993 — intervention group
Group type: COMPARATOR
Intervention: Prescribed aerobic exercise
Number of subjects: 220
Study 38950993 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 220
Study 38950997 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard inactivated quadrivalent influenza vaccine
Number of subjects: 100
Study 38950997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 38951007 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0
Study 38951007 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Oxygen by Nasal Cannula (HFNC)
Number of subjects: 0
Study 38951007 — intervention group
Group type: COMPARATOR
Intervention: Standard Oxygen Therapy
Number of subjects: 0
Study 38951006 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong Families programme (7-hour family skills group intervention over 3 weeks)
Number of subjects: 90
Study 38951006 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group (control)
Number of subjects: 90
Study 38951006 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong Families programme
Number of subjects: 90
Study 38951008 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest in pregnancy following diagnosis
Number of subjects: 1302
Study 38951008 — intervention group
Group type: EXPERIMENTAL
Intervention: Fertility preservation
Number of subjects: 1302
Study 38951008 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy rates
Number of subjects: 1302
Study 38951008 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial outcomes
Number of subjects: 1302